US Patent

US10968453 — Compositions for modulating SOD-1 expression

Method of Use · Assigned to Biogen MA Inc · Expires 2035-04-01 · 9y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for decreasing SOD-1 expression to treat or prevent amyotrophic sclerosis (ALS) and other SOD-1 associated diseases.

USPTO Abstract

Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3575 Qalsody

Patent Metadata

Patent number
US10968453
Jurisdiction
US
Classification
Method of Use
Expires
2035-04-01
Drug substance claim
No
Drug product claim
No
Assignee
Biogen MA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.